PL
BLCM

Plancorp LLC’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Plancorp LLC’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,155
Closed -$71K – 176
2018
Q3 		$71K Buy
+1,155
New +$78.2K 0.03% 171

Other funds holding BLCM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Plancorp LLC's BLCM Position: Q4 2018 in Review

Plancorp LLC sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2018, closing a stake of 1,155 shares — an estimated $71K sold.

Plancorp LLC first reported a position in BLCM in Q3 2018 and held it in 1 quarter. The position peaked at $71K in Q3 2018. 92 funds tracked by Wall St. Rank hold BLCM as of Q4 2018.

  • Plancorp LLC reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Plancorp LLC sold 1,155 Bellicum Pharmaceuticals, Inc. shares in Q4 2018, an estimated $71K.
  • Plancorp LLC first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
  • Plancorp LLC's Bellicum Pharmaceuticals, Inc. position peaked at $71K in Q3 2018.
  • 92 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2018.

Based on Plancorp LLC's 13F filing for Q4 2018, filed 14 Feb 2019.